DK2838539T3 - Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser - Google Patents
Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelserInfo
- Publication number
- DK2838539T3 DK2838539T3 DK13714917.5T DK13714917T DK2838539T3 DK 2838539 T3 DK2838539 T3 DK 2838539T3 DK 13714917 T DK13714917 T DK 13714917T DK 2838539 T3 DK2838539 T3 DK 2838539T3
- Authority
- DK
- Denmark
- Prior art keywords
- estrogender
- derivatives
- treatment
- neurological disorders
- neurological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12164741.6A EP2653163A1 (en) | 2012-04-19 | 2012-04-19 | Estrogenic components for use in the treatment of neurological disorders |
| PCT/EP2013/057279 WO2013156329A1 (en) | 2012-04-19 | 2013-04-08 | Estrogenic components for use in the treatment of neurological disorders. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2838539T3 true DK2838539T3 (da) | 2017-11-27 |
Family
ID=48050711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13714917.5T DK2838539T3 (da) | 2012-04-19 | 2013-04-08 | Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9238035B2 (da) |
| EP (2) | EP2653163A1 (da) |
| JP (1) | JP6139662B2 (da) |
| CN (1) | CN104379148B (da) |
| AU (1) | AU2013248481B2 (da) |
| CA (1) | CA2869902C (da) |
| CY (1) | CY1119603T1 (da) |
| DK (1) | DK2838539T3 (da) |
| ES (1) | ES2647111T3 (da) |
| HR (1) | HRP20171627T1 (da) |
| HU (1) | HUE034902T2 (da) |
| LT (1) | LT2838539T (da) |
| NO (1) | NO2838539T3 (da) |
| PL (1) | PL2838539T3 (da) |
| PT (1) | PT2838539T (da) |
| RS (1) | RS56595B1 (da) |
| RU (1) | RU2627846C2 (da) |
| SI (1) | SI2838539T1 (da) |
| WO (1) | WO2013156329A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6425540B2 (ja) | 2011-06-01 | 2018-11-21 | エステトラ エス．ペ．エール．エル． | エステトロール中間体を製造するための方法 |
| RS55293B1 (sr) | 2011-06-01 | 2017-03-31 | Estetra Sprl | Postupak proizvodnje intermedijara estetrola |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| US11638745B2 (en) * | 2015-05-20 | 2023-05-02 | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education | Method to improve neurologic outcomes in temperature managed patients |
| EP3310345B1 (en) | 2015-06-18 | 2021-03-31 | Estetra SPRL | Orodispersible tablet containing estetrol |
| CA2988495C (en) | 2015-06-18 | 2022-02-08 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| HUE054551T2 (hu) * | 2015-06-18 | 2021-09-28 | Estetra Sprl | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CN107260712A (zh) * | 2017-06-22 | 2017-10-20 | 中国人民解放军第三军医大学 | 奥培米芬在制备促进髓鞘形成和再生的药物中的应用 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| CN113243332B (zh) * | 2020-02-07 | 2023-07-28 | 上海市东方医院（同济大学附属东方医院） | 一种广泛脑区神经元树突发育障碍动物模型的制备与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038636A2 (en) * | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Estriol therapy for autoimmune and neurodegenerataive diseases and disorders |
| GB2378898A (en) * | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
| US7923440B2 (en) * | 2002-06-11 | 2011-04-12 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| AU2003274943A1 (en) | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | Use of estetrol and analogues for treating or preventing cardiovascular pathologies, in particular atherosclerosis |
| US20090221540A1 (en) * | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| WO2008156365A1 (en) * | 2007-06-21 | 2008-12-24 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
| EP2214488B1 (en) * | 2007-11-06 | 2016-12-21 | Signal Coordinating Therapy, Inc. | Compositions and methods for treating parkinson's disease and related disorders |
| CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
-
2012
- 2012-04-19 EP EP12164741.6A patent/EP2653163A1/en not_active Withdrawn
-
2013
- 2013-04-08 CN CN201380020555.6A patent/CN104379148B/zh active Active
- 2013-04-08 DK DK13714917.5T patent/DK2838539T3/da active
- 2013-04-08 NO NO13714917A patent/NO2838539T3/no unknown
- 2013-04-08 LT LTEP13714917.5T patent/LT2838539T/lt unknown
- 2013-04-08 HU HUE13714917A patent/HUE034902T2/hu unknown
- 2013-04-08 SI SI201330825T patent/SI2838539T1/sl unknown
- 2013-04-08 RU RU2014145800A patent/RU2627846C2/ru active
- 2013-04-08 RS RS20171122A patent/RS56595B1/sr unknown
- 2013-04-08 JP JP2015506173A patent/JP6139662B2/ja active Active
- 2013-04-08 PL PL13714917T patent/PL2838539T3/pl unknown
- 2013-04-08 EP EP13714917.5A patent/EP2838539B1/en active Active
- 2013-04-08 AU AU2013248481A patent/AU2013248481B2/en active Active
- 2013-04-08 US US14/395,465 patent/US9238035B2/en active Active
- 2013-04-08 CA CA2869902A patent/CA2869902C/en active Active
- 2013-04-08 PT PT137149175T patent/PT2838539T/pt unknown
- 2013-04-08 WO PCT/EP2013/057279 patent/WO2013156329A1/en active Application Filing
- 2013-04-08 ES ES13714917.5T patent/ES2647111T3/es active Active
-
2017
- 2017-10-25 HR HRP20171627TT patent/HRP20171627T1/hr unknown
- 2017-11-14 CY CY20171101193T patent/CY1119603T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9238035B2 (en) | 2016-01-19 |
| PL2838539T3 (pl) | 2018-01-31 |
| EP2653163A1 (en) | 2013-10-23 |
| CN104379148A (zh) | 2015-02-25 |
| CY1119603T1 (el) | 2018-04-04 |
| SI2838539T1 (sl) | 2017-12-29 |
| RU2014145800A (ru) | 2016-06-10 |
| HRP20171627T1 (hr) | 2017-12-01 |
| CN104379148B (zh) | 2017-08-25 |
| AU2013248481A1 (en) | 2014-10-30 |
| RS56595B1 (sr) | 2018-02-28 |
| EP2838539B1 (en) | 2017-08-16 |
| EP2838539A1 (en) | 2015-02-25 |
| AU2013248481B2 (en) | 2017-02-16 |
| PT2838539T (pt) | 2017-11-15 |
| US20150133419A1 (en) | 2015-05-14 |
| NO2838539T3 (da) | 2018-01-13 |
| CA2869902A1 (en) | 2013-10-24 |
| JP2015514731A (ja) | 2015-05-21 |
| ES2647111T3 (es) | 2017-12-19 |
| CA2869902C (en) | 2019-07-02 |
| HUE034902T2 (hu) | 2018-03-28 |
| JP6139662B2 (ja) | 2017-05-31 |
| RU2627846C2 (ru) | 2017-08-14 |
| WO2013156329A1 (en) | 2013-10-24 |
| LT2838539T (lt) | 2017-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
| DK2838539T3 (da) | Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK2938740T3 (da) | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser | |
| DK2800581T3 (da) | Fremgangsmåder til behandling af adfærdssymptomer på neurologiske og mentale forstyrrelser | |
| DK2961410T3 (da) | Anvendelse af pyrazolopyrimidinderivater til behandlingen af pi3k relaterede lidelser | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| CO6751293A2 (es) | Derivados heterocíclicos novedosos y su uso en e tratamiento de trastornos neurológicos | |
| DK2836200T3 (da) | Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium | |
| DK2830662T3 (da) | Fremgangsmåder til behandlng af hårtabsforstyrrelser | |
| DK2981269T3 (da) | Behandling af stofskifteforstyrrelser hos hestedyr | |
| DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| DK2782566T3 (da) | L-serin til anvendelse ved behandling af neurodegenerative lidelser | |
| DK2830645T3 (da) | Neuregulin til anvendelse i behandling af perifær nervelæsion | |
| HK1204573A1 (en) | Treatment of inflammatory skin disorders | |
| SMT201600395B (it) | Derivati di pantotenato per il trattamento di disturbi neurologici | |
| DK2819667T3 (da) | Retinalderivater til anvendelse til forbedring af synsfunktionen | |
| DK2961426T3 (da) | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g | |
| DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
| DK2705847T3 (da) | Sammensætning til behandling af psoriasis | |
| HK1221166A1 (zh) | 炎症性病症的治療 | |
| DK3447070T3 (da) | Forbindelser til behandling af remyeliniseringsblokaden i sygdomme relateret til udtrykket af herv-w kappeprotein | |
| DK3351554T3 (da) | Glutenrelaterede forstyrrelser |